Clinical Trial Update: Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study update evaluating the absolute oral bioavailability of dabrafenib (GSK2118436) when co-administered with an intravenous radiolabeled microtracer i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Dabrafenib (Dabrafenib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 1 | Status: COMPLETED